In the lat­est set­back to Vi­cal/Astel­las part­ner­ship, lead CMV vac­cine fails a piv­otal PhI­II study

When Vi­cal’s lead vac­cine flopped in a Phase II her­pes study in 2016, the biotech and its part­ners at Astel­las switched fo­cus to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.